Drug Profile


Alternative Names: [18F]DCFPyL; DCFPyL-18F; PyL™

Latest Information Update: 12 Jun 2017

Price : $50

At a glance

  • Originator Johns Hopkins University School of Medicine
  • Developer National Cancer Institute (USA); Progenics Pharmaceuticals
  • Class Antineoplastics; Imaging agents; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Prostate cancer

Most Recent Events

  • 14 Jun 2017 National Cancer Institute plans a phase II trial for Prostate cancer(Diagnosis) in USA (NCT03181867)
  • 06 Jun 2017 Phase-II clinical trials in Prostate cancer (Diagnosis, Metastatic disease) in USA (IV) (NCT03173924)
  • 25 Apr 2017 Progenics Pharmaceuticals has patents pending for fluorine-18-DCFPyL worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top